remodl-b: bortezomib r-chop versus r-chop in patients with dlbcl
Published 1 year ago • 123 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
1:00
phase ib trial of r-chop plus iberdomide or golcadomide in aggressive b-cell lymphoma
-
5:45
insights into the remodl-a trial: acalabrutinib plus r-chop for patients with dlbcl
-
2:56
upcoming trials for dlbcl: r-chop with acalabrutinib and obinutuzumab with checkpoint inhibitor
-
2:43
first report of phase 3 robust trial: r2-chop for frontline dlbcl
-
2:55
clinical activity of abemaciclib in patients with r/r mcl
-
2:25
efficacy of varnimcabtagene autoleucel in patients with r/r bcl with no indication for car-t therapy
-
1:06
derive trial update: did vs dvd in newly diagnosed mm
-
21:38
drawing the line: the rationale behind blood tube collection order
-
23:33
mindray hematologi bc-3200 baground abnormal
-
5:45
lkb historange microtome.wmv
-
1:45
the role of non-covalent btkis in the era of covalent btkis for b-cell malignancies
-
2:01
the evolution of bcl2 inhibition in cll
-
1:10
venbd in r/r mm: updated analysis of bellini
-
1:31
evaluating myc, bcl2 and bcl6 expression to define double-expressor lymphoma
-
1:44
real-world outcomes of brexu-cel for r/r b-all: evidence from the cibmtr registry
-
1:24
predictive biomarkers of response to venbd in r/r mm
-
5:55
ian flinn, md: bendamustine plus rituxmab outperforms r-chop in long-term bright follow-up
-
5:44
glofitamab and obinutuzumab in r/r mcl
-
1:46
the value of mosunetuzumab in r/r fl
-
2:50
insights into the ca057-003 trial: mezigdomide, tazemetostat & dexamethasone for r/r myeloma
-
2:31
relevance trial analysis: investigating the impact of lymphocyte/monocyte ratio on patient outcomes
-
0:55
updated results of the bruin trial: pirtobrutinib in r/r mcl